TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsOver 4 million doses of Sinopharm vaccine administered in emergency use
Two vaccines respectively from two institutes owned by CNBG, a unit of state-backed China National Pharmaceutical Group (Sinopharm), are included in China's emergency vaccination scheme, which was officially started in July targeting specific groups of people facing a high infection risk.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
A picture shows the Manama's repurposed convention centre, in which 6,000 people are participating in a large-scale trial of a Chinese-sponsored vaccine for the Covid-19 coronavirus, on August 27, 2020 in the Bahraini capital. Chinese drug giant Sinopharm began testing the inactivated COVID-19 jab in Bahrain earlier this month after starting a similar trial on 15,000 subjects in the nearby United Arab Emirates in July. The current phase of the study, in which the vaccine's efficacy and safety is tested in a large cross-section of the population, is due to last until July 2021.
(AFP/Mazen Mahdi)
M
ore than 4 million COVID-19 vaccine doses from China National Biotec Group (CNBG) have been administered as of Jan. 4 via China's emergency use program, the company's parent firm said late on Thursday.
Two vaccines respectively from two institutes owned by CNBG, a unit of state-backed China National Pharmaceutical Group (Sinopharm), are included in China's emergency vaccination scheme, which was officially started in July targeting specific groups of people facing a high infection risk.
"No serious adverse reaction was reported in large-scale emergency use of Sinopharm's COVID-19 vaccines," Sinopharm said on Chinese social media WeChat.
A total of 72,000 people have been overseas after receiving China's emergency jabs, including around 40 percent of more than 5,000 staffers on one Chinese firm's Pakistan-based project, Sinopharm said.
None of the vaccinated diplomats, international organization representatives or employees at Chinese firms, who went to countries of high virus risk, contracted the COVID-19 disease caused by the new coronavirus, despite their close contact with infected locals, Sinopharm said.
The firm did not break down the number of doses for each of the two vaccines used in the emergency program.
Aside from CNBG's two vaccines, China's emergency use program also includes a potential shot from Sinovac Biotech. A fourth candidate from CanSino Biologics was approved for use in Chinese military personnel.
The vaccine from CNBG's unit Beijing Institute of Biological Products was approved in China for broader use among the general public last year. The two-dose regimen is 79.34 percent effective against the disease, according to interim analysis from late-stage clinical trials overseas.
Although the CNBG vaccine's protection rate is lower than the more than 90 percent efficacy of vaccines from Moderna or Pfizer and its partner BioNTech SE, it can be transported and stored at less demanding temperatures
